Veterinary Infectious Disease Diagnostics Market is predicted to grow at a 9.0% CAGR through 2032

[330 Pages Report] From US$ 1.5 billion in 2021 to US$ 3.8 billion in 2032, the veterinary infectious disease diagnostics market is predicted to grow at a 9.0% CAGR through 2032, finds an exclusive report by Future Market Insights.

As per veterinary infectious disease diagnostics market study, there is a rise in the number of pets, the rising incidence of zoonotic diseases, the growing adoption for animal-derived food products, the rising demands for pet insurance, the upsurge in animal health expenditure, and the surge in the number of veterinary practitioners and income levels in developed economies which are contributing to the veterinary infectious disease diagnostics market growth.

The overall veterinary infectious disease diagnostics market growth is projected to be hindered by rising pet care expenses. One of the critical challenges restricting veterinarians’ adoption of veterinary infectious disease diagnostics is a dearth of skilled veterinarians and diagnostic infrastructure, particularly in developing countries. Another key hindrance to broader adoption is the expensive cost of modern diagnostic tests.

The COVID-19 pandemic is predicted to have a temporary and moderate effect on the veterinary infectious disease diagnostics market during the forecast period.

On a global scale, there has been an increase in the overall companion animal population and adoption rate. As a result, demand for pet care products and services are predicted to rise as the pet population grows, supporting the growth of related sectors such as veterinary infectious disease diagnostics.

Although the pet insurance industry is growing, the number of animals covered for treatment remains low. As a result, the animal’s owner usually bears the majority of the cost of treatment. Along with the rising cost of pet insurance, the cost of veterinary diagnostic lab treatment is also rising at a rapid pace.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14276

The majority of veterinary clinics have basic veterinary laboratory testing capabilities.

Veterinary practitioners are under pressure to raise their fees due to the lower pay in this sector compared to other advanced-degree professions such as dentistry and law. In addition, high pet care expenses directly impact the number of visits pet owners make to veterinary lab facilities, limiting the veterinary infectious disease diagnostics market growth.

In the present COVID-19 pandemic, testing has shown that the virus travels more from animal diagnostics to the animal than from human to human or human to animal. Therefore, the demand for PCR panels for virus testing is projected to rise as more pet owners begin testing their animals for the absence of these diseases. This will unlock the veterinary infectious disease diagnostics opportunity for new molecular diagnostics panels to enter the vet lab market.

There is a significant imbalance between veterinary diagnostics demand and supply for veterinary specialists in developing economies such as Brazil, China, and Southeast Asia. The majority of veterinarians operate in private vet labs dedicated to companion animals around the world, resulting in a scarcity of resources for agricultural or food-producing animals.

According to end-users, reference laboratories are likely to dominate veterinary infectious disease diagnostics market growth. The veterinary diagnostics market is being bolstered by an increase in the number of samples for examination and an increase in in-house testing.

The Asia-Pacific area is set to grow lab for vets at a breakneck pace. Veterinary Infectious Disease Diagnostics manufacturers and important players will find attractive prospects in emerging economies like China, India, and South Korea. The region’s market is developing due to rising zoonotic disease occurrences and demand for infectious disease diagnostics.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14276

Key Takeaways

  • The highest veterinary infectious disease diagnostics market is further expected to reach US$ 3.8 Bn by 2032.
  • According to AVMA, there were around 26,000 veterinary hospitals & clinics in the U.S. in 2019, and more than 80% of them provided point-of-care testing.
  • The consumables, reagents & kits product segment held the largest veterinary infectious disease diagnostics market share of more than 52% in 2021.
  • The study finds that Asia-Pacific has the highest veterinary infectious disease diagnostics market growth, which is growing due to the contribution of the following emerging countries such as India, with a CAGR of 11.7%.
  • The non-infectious diseases segment held the maximum veterinary infectious disease diagnostics market share of more than 27% of the global revenue in 2021.
  • The pathology testing type segment dominated the veterinary infectious disease diagnostics market in 2021 with a share of more than 13% owing to its wide variety of service offerings, such as various lab tests, imaging, and specialized tests.
  • The laboratories segment held the largest revenue share of more than 37% in 2021.

Competitive LandscapeThe veterinary infectious disease diagnostics market is competitive, with only a few leading competitors.

Due to their significant regional footprint in many locations, these critical veterinary infectious disease diagnostics manufacturers had a strong market position. Biomerieux S.A., Heska Corporation, IDVet, IDEXX veterinary Laboratories, Inc., and Indical Bioscience are some market leaders.

Recent Developments in the Veterinary Infectious Disease Diagnostics Market

  • INDICAL BIOSCIENCE GmbH (Germany) acquired the Svanova product portfolio from Boehringer Ingelheim in April 2021, allowing INDICAL to expand its portfolio by 25 assays for cattle.
  • BioChek (Netherlands) expanded to Johannesburg, South Africa, in April 2021.
  • Lacuna Diagnostics (US) was acquired by Heska Corporation (US) in January 2021, bolstering the company’s portfolio of point-of-care digital cytology technology and telemedicine services.
  • NEOGEN Corporation (US) partnered with Transnetyx Inc. (US) in November 2020, allowing NEOGEN to expand its footprint in the animal genomics and diagnostics sector.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14276

Veterinary Infectious Disease Diagnostics Market Key Segments By Technology:

  • Immunodiagnostics
  • Molecular Diagnostic
  • Others

By Animal Type:

  • Companion animal
  • Food-producing animals

By End User:

  • Reference Laboratories
  • Veterinary Hospitals and Clinics
  • Point of Care
  • Research Institutes & Universities

Point-of-care Molecular Diagnostics Market is forecasted to move forward at an average pace and register a CAGR of 8% from 2022 to 2032.

[321 Pages Report] Per the point-of-care molecular diagnostics market survey by Future Market Insights (FMI), the market is forecasted to move forward at an average pace and register a CAGR of 8% from 2022 to 2032.

Many current POC diagnostics are based on lateral flow immunoassay technology, and these instruments use antibodies to detect the presence of an analyte, such as cancer biomarkers, in a short period and thus, having the effect of spurring the point-of-care molecular diagnostics market growth to a large extent.

As per the point-of-care molecular diagnostics market report, the demand for point-of-care molecular diagnostics is on a surge owing to the growing trend toward preventive medicine. This is considered to shape the point-of-care molecular diagnostics future trends to a large extent.

According to United Nations data, the number of older adults has steadily increased for decades. As a result of this demographic shift, the prevalence of various chronic diseases is rising, thereby facilitating the adoption of point-of-care molecular diagnostics devices.

The study finds that current cancer diagnostic methods are invasive (for example, cystoscopy, which involves inserting a hollow tube/cystoscope installed with a lens into the urethra and bladder to diagnose cancer). However, less invasive methods, such as point-of-care molecular tests, can be available for point-of-care cancer diagnostics, broadening the point-of-care molecular diagnostics opportunities.

Though most of the industries’ overall sales of molecular diagnostics dwindled steeply due to the COVID-19 pandemic and the use of molecular diagnostic methods for COVID-19 testing, it had a positive impact on the point-of-care molecular diagnostics market size.

As countries gradually slacken their restrictions on movement, there is a resurgence in testing numbers. Aside from vaccines and therapeutic drugs, there is an increasing demand for the development of more precise and simple testing technologies and the expansion of testing structures.

Thus, point-of-care molecular diagnostics companies have made strategic decisions to introduce POC rapid tests, maintain revenue, and mitigate COVID-19’s impact on their operational capabilities. This point-of-care molecular diagnostics market trend is expected to continue in the coming years.

Aside from cancer in the elderly, respiratory diseases in children and adults are becoming one of the top five causes of death. However, as per Pfizer, there are currently no RSV immunization options available, although many vaccines are still in clinical trials.

People are dying due to this since they are unaware of the available treatment. Thus, the prevalence of point-of-care molecular diagnostic tests plays a vital role in quick analysis and, as a result, in providing patients with immediate treatment.

The point-of-care molecular diagnostics market is predicted to muster a total revenue of around US$ 4 Bn by 2026 on account of the abovementioned factors.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14279

Key Takeaways

  • The assays and kits segment is expected to account for a significant chunk of the POC molecular diagnostics market based on the product type. The market growth of this segment is being driven by the widespread purchase of these products’ POC diagnostic devices as a result of their frequent usage.
  • The RT-PCR segment is expected to dominate the point-of-care molecular diagnostics market in terms of technology, owing to the increasing use of RT-PCR in proteomics, genomics, and COVID-19 testing and the availability of portable, easy-to-use POC devices.
  • The respiratory diseases segment is projected to lead the POC molecular diagnostics market on account of the shift of concentration by key players on various strategies for developing advanced point-of-care diagnostics devices.
  • By end-use, the hospital bedside segment is expected to witness the most significant point-of-care molecular diagnostics market share due to the rising adoption of advanced instruments in these settings and rapid investments in hospital infrastructure by the public and private sectors in emerging countries.
  • The Asia Pacific region is expected to proliferate due to the expansion of key market players, a lack of sophisticated central laboratory point-of-care molecular testing services, and the potential cost-effectiveness of POC molecular diagnosis.

“The North American market is expected to be at the forefront of the point-of-care molecular diagnostics market, attributable to the United States’ emerging trends in point-of-care molecular diagnostics market such as well-organized health-care system. In addition, the system promotes research and development. These policies encourage foreign players to enter the United States and the North American market. As a result, many global market players are present in this region, and the market is projected to flourish as high demand is met by the presence of global players in the region.” opines an FMI researcher.

Competitive Landscape

The top point-of-care diagnostics companies are developing most point-of-care molecular diagnostic tests and have established their market position by investing more in research and developing a better distribution system.

The entry of new players challenges the semi-consolidated market and may result in intense competition during the forecast period.

Furthermore, due to increased awareness, the Asia-Pacific region is seeing the emergence of some minor players, which aided the point-of-care molecular diagnostics market growth.

LLC. (US), Danaher Corporation (US), Alere Inc. (US), Quidel Corporation (US), Biocartis Group NV (Belgium), bioMérieux SA (France), Thermo Fisher Scientific (US), Mesa Biotech Inc. (US), F. Hoffmann-La Roche Ltd., and Meridian Bioscience Inc. (US) are the critical point-of-care diagnostic companies profiled in the global POC molecular diagnostics market.

Recent developments in the point-of-care molecular diagnostics market are as follows:

  • The World Health Organization (WHO), Africa Centers for Disease Control and Prevention (Africa CDC), the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Foundation for Innovative New Diagnostics (FIND), and the Global Fund constituted a global partnership. Today, the organization announced the launch of the COVID-19 rapid test in low and middle-income countries.
  • Mylab Discovery Solutions has collaborated with Hemex Health, the United States company, to develop next-generation diagnostic solutions for coronavirus and another point-of-care diagnostic testing.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14279

Point-of-care Molecular Diagnostics Market Key Segments

By Product & Service:

  • Assays & kits
  • Instruments & Analyzers
  • Software & Services

By Technology:

  • RT-PCR
  • INAAT
  • Other technologies

By Application:

  • Respiratory Diseases
  • Sexually Transmitted Diseases
  • Hospital-acquired Infections
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Other Applications

By End User:

  • Physicians’ Offices
  • Hospitals & ICUs
  • Research Institutes
  • Other End Users

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Cleanroom Technologies Market is projected to expand at a CAGR of 6% to US$ 13.29 Billion by 2032

[334 Pages Report] The cleanroom technologies market study conducted by Future Market Insights is projected to expand at a CAGR of 6% to US$ 13.29 Bn by 2032, up from US$ 7 Bn in 2021. The rising demands for sterilized pharmaceutical formulations and the growing demand for medical device cleanrooms are driving this cleanroom technologies market growth.

In the subsequent years, technological advancements in cleanroom technology and rising demand for cleanroom technologies in developing economies are likely to provide significant cleanroom technologies market potential possibilities.

The study finds that cleanroom technologies market constraints associated with their operational expenses and the technical problems associated with modifying cleanroom designs in developing economies are hampering the cleanroom technologies market growth.

ISO 6 cleanrooms and ISO 8 cleanrooms have different prices per square foot. This is due to the fact that the volume of air delivered in both types of cleanrooms differs. In an ISO 6 cleanroom, the air is 100 times cleaner than in an ISO 8 cleanroom, increasing the air conditioning capacity of the HVAC systems.

The demand to maintain an antimicrobial environment by eliminating airborne particles in these facilities increases as the number of hospitals and Ambulatory Surgery Centers (ASCs) grows due to the various perks they provide.

There are no defined cleanroom design standards for various application areas or product types. This presents several difficulties for cleanroom technologies manufacturers, as they must adhere to various designs each time. There are no requirements for environmental, product, or facility factors to be controlled in the legislation. Instead, they only give requirements that a corporation must follow after manufacturing a product in a cleanroom setting.

Consumables dominated the cleanroom technology market in 2020, accounting for the most revenue. Another critical factor attributing to the segment’s highest cleanroom technology market share is the frequent usage of consumables and high sales of cleanroom consumables, notably gloves.

Due to the particular sensitivity of processes, cleanroom technology is vital for biotechnology-based operations such as research and development, biocontamination control, pilot studies, and production facilities. Consequently, demand for cleanroom technology is anticipated to grow as the biotechnology industry grows significantly over the forecast period.

According to the report, North America dominated the cleanroom technology market, accounting for most sales of cleanroom technology.

This is due to the region’s well-established healthcare infrastructure, the presence of significant pharmaceutical and medical device cleanroom businesses on the ground, an increase in the burden of non-communicable diseases, and growth in cosmeceutical and nutraceutical awareness. Moreover, restrictive laws governing the approval of healthcare items in this region, such as the United States, have boosted demand for cleanroom technology.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14283

“The cleanroom technology market has seen an increase in funding from government agencies and private groups to fund R&D operations in small businesses attempting to commercialize their initial findings.”

Key Takeaways:

  • The consumables segment leads the cleanroom technology market in 2020, accounting for 54.1% of total revenue.
  • In 2020, the pharmaceutical industry segment was expected to dominate the cleanroom technology market by end-use, accounting for 40.3% of total revenue.
  • Due to the increased acceptance of biotechnology commodities worldwide, the biotechnology industry segment in the cleanroom technologies market is predicted to develop at the fastest rate of 7.2% over the forecast period.
  • The equipment segment held a dominant position in the cleanroom technologies market in 2019, accounting for 74.2% share in terms of value.
  • North America held the largest cleanroom technology market share in 2020, accounting for 35.5% of total revenue.

Competitive Landscape:

The cleanroom technology market is highly fragmented, with more regional competitors than cleanroom technology market manufacturers present. Mergers and acquisitions, as well as R&D relating to modular cleanroom systems’ developments, are some of the major strategies used by leading firms to grow their cleanroom technology market share.

The major cleanroom technology market manufacturers covered in the cleanroom technology market report are Simplex Isolation Systems, AES Clean Technology, DuPont, Clean Air Products, Clean Room Depot, Inc., Integrated Cleanroom Technologies Private Limited, Hemair, AIRTECH JAPAN, Ltd., Lennox International Inc., COLANDIS GMBH, ABN Cleanroom Technology, Nicos Group, Inc., Galvani S.r.l., ANSELL LTD., Ardmac, Azbil Corporation, novum. Reinraumtechnik, Helapet Ltd., KCWW, Camfil, Labconco, Taikisha Ltd, Terra Universal. Inc. and Lindner Group, among other domestic and universal cleanroom technologies market manufacturers.

  • Ansell Limited announced in January 2021 that it had finalized the acquisition of the Primus brand and related assets that make up Primus Gloves and Sanrea Healthcare Products’ Life Science division on December 31, 2020. In addition, Ansell and Primus have formed a long-term supply alliance.
  • May 2020 – A ground-breaking ceremony was staged by Qioptiq, a subsidiary of Excelitas Technologies, to commemorate the start of construction on a new plant in Germany. The original acreage of the new site is roughly 18,000 sqm. This expansion of the company’s production capacities is expected to cost around USD 27 million. State-of-the-art ISO 5 cleanrooms and other production-related offices will be housed in the proposed building.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14283

Key Segments By Product Type:

  • Equipment
  • Fan Filter Unit (FFU)
  • HVAC Systems
  • Laminar Air Flow Systems and Biosafety Cabinets
  • HEPA Filters
  • Air Diffusers and Showers
  • Safety Consumables
  • Cleaning Consumables

By End User:

  • Pharmaceuticals Industry
  • Biotechnology Industry
  • Medical Device Manufacturer
  • Hospitals

By Construction Type:

  • Standard/Drywall Cleanroom
  • Hardwall Cleanroom
  • Softwall Cleanrooms
  • Terminal Boxes

By Region:

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Nucleic Acid Isolation and Purification Market exhibiting growth at a CAGR of 5.6% during the forecast period 2022-2029

Future Market Insights (FMI), in its latest publication, outlines the future trajectory of the global nucleic acid isolation and purification market through 2029. According to the report, worldwide sales of nucleic acid isolation and purification kits were valued at ~US$ 994 million in 2022, and are estimated to register a Y-o-Y growth of ~4% in 2022. As the consistency and reliability of molecular diagnostic results relies heavily on the quality of genetic material i.e. DNA and RNA, manufacturers are focusing on offering high-quality products, ensuring improved yield and purity.

With growing need to understand and characterize microbial diversity, including that associated with human body, governments as well as private companies are increasingly investing in life science projects, thereby creating a greater demand for nucleic acid isolation and purification. While the high cost challenge persists, shortage of skilled professionals in healthcare and biopharma industries remain the longstanding challenges.

Get a Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-10035

“Rapid and efficient methods or products to extract genomic RNA and DNA from virtually any biological sample have been growing in demand to ensure the success of downstream applications in molecular biology. With growing research on detection of tumor specific changes, FMI study finds that nucleic acid isolation and purification market vendors are exploring new technologies to facilitate ease-of-use and minimize user-error of their products.”

Future market Insights’ study reveals that the nucleic acid isolation and purification market is likely to expand at a CAGR of ~5.6% during the period 2022-2029. One of the key influencing factors is manufacturers’ focus to direct their investments towards advanced technologies such as magnetic-bead or bead-beating technology, to align with end users’ demand for an effective system for extraction of high-quality starting material and efficient inhibitor removal. The unique challenges for extracting and purifying nucleic acid from different organisms and tissue types, have also brought more focus on customized systems and solutions.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-10035

Advances in Microbiome Research to Dictate Manufacturers’ Growth Strategies

In comparison with RNA isolation kits, manufacturers continue to increase innovations and production of DNA isolation kits, as the category is expected to account for larger share in the market during the forecast period. As per the study, lucrative opportunities are identified in increasing application scope of DNA isolation and purification kits in various academic research institutes, contract research organizations, and biotechnologies companies to not only successfully extract the DNA but also to minimize the presence of contaminants and prevent nucleic acid degradation during preparation.

As genomic and microbiome research advances, manufacturers are working on automating the nucleic acid isolation and purifications kits to recover DNA and RNA from the toughest samples used in microbiome work such as soil and stool samples.

Growth prospects of the nucleic acid isolation and purification market, as the study opines, are relatively high in developed countries of North America and Europe. Hefty investments in R&D on molecular biology and precision medicines over gradual increase in the prevalence of cancer, genetic disorders, and complex diseases are likely to influence the manufacturers to enhance their production capabilities.

Tapping into opportunities in China and Japan for acquiring local players and increasing manufacturing facilities will provide the added advantage to gain a new customer base. As innovations zoom in, a number of market players are working on offering products that are free of toxic organic solvents and enable cost-effective method to extract and purify PCR-ready DNA or RT-PCR-ready RNA from numerous samples.

The report also offers an incisive outlook on the competitive landscape of nucleic acid isolation and purification market. As per the study, extensive M&A activities and new launches remain the key focus areas of the market players. In addition, they are emphasizing on strengthening outsourcing and solutions through strategic collaborations.

Ask Us Your Questions About This Report: https://www.futuremarketinsights.com/ask-question/rep-gb-10035

Nucleic Acid Isolation and Purification Market by Category

By Product:

  • DNA Extraction and Purification Kits
    • Column Based Kits
    •  Magnetic Beads
    •  Reagent Based Kits
  • RNA Extraction and Purification Kits
    • Column Based Kits
    • Magnetic Beads
    •  Reagent Based Kits

By Application:

  • Plasmid Isolation and Purification
  • DNA Isolation and Purification
  • RNA Isolation and Purification

By End User:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

 

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

HDL Cholesterol Kits Market Expanding at a healthy 4.8% CAGR, the market size is projected to total US$ 786.2 Mn by 2029

The growth of the HDL cholesterol kits market can be attributed to the increasing prevalence of atherosclerosis due to high cholesterol level, which favours the demand for cholesterol testing. According to the latest research by FMI, the global HDL cholesterol kits market is expected to be valued at US$ 786.2 Mn by the end of 2029. The HDL cholesterol kits market is expected to expand at a CAGR of 4.8% during the forecast period 2022-2029.

The increasing incidence of obesity and hyperlipidaemia among people is boosting the need for cholesterol testing, which is driving the growth of the HDL cholesterol kits market. The prevalence of obesity has increased from 33.7% in 2007-2008 to 39.7% in 2015-2016 among adults in the U.S. The increasing prevalence of obesity also increases the risk of cardiovascular disorders, high blood pressure, and hyperlipidaemia.

Moreover, the prevalence of hyperlipidaemia is high among the obese population. Nearly 60-70% of patients suffering from obesity have hyperlipidaemia. Other factors, such as growing awareness programs for cholesterol testing and growing cholesterol testing among diabetic patients, are also propelling the growth of the HDL cholesterol kits market.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9842

Rise of ‘Regular Health Check’ Trend Uplifts Prospects in East Asia

Low awareness in middle- and low-income countries about cholesterol testing and other healthcare testing are also among the major factors that are expected to hamper the growth of the HDL cholesterol kits market.

There is low awareness about diseases such as dyslipidaemia and hypercholesterolemia in middle-income countries and rural areas. Moreover, the chances of errors and inaccuracy in HDL cholesterol testing methods, such HDL cholesterol precipitating method, are among factors expected to restrain the growth of the HDL cholesterol kits market.

The North America HDL cholesterol kits market gain a maximum value share in 2021. However, the East Asia HDL cholesterol kits market expected to witness prominent growth owing to the higher demand for cholesterol testing in countries such as China and Japan.

Developing countries, such as China and India, represent a significant growth rate in the HDL cholesterol kits market due to the growing adoption of regular healthcare testing. The Middle East & Africa HDL cholesterol kits market is expected to witness a sluggish growth rate as compared to other regions.

The global HDL cholesterol kits market has been studied based on the product type and end user. Based on the product type, the HDL cholesterol kits market has been segmented into HDL cholesterol precipitating reagent kit, HDL cholesterol direct reagent kit, and HDL and LDL/VLDL assay kit.

The HDL and LDL/VLDL assay kit product type segment is expected to hold a prominent share in the global HDL cholesterol kits market. Based on end user, the HDL cholesterol kits market has been segmented into hospitals, clinics, and diagnostic laboratories. In terms of revenue, the hospitals segment of the HDL cholesterol kits market was a significant market for HDL cholesterol kits in 2021.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-9842

Partnerships and Acquisitions Governing the Competition Landscape

Some of the key players operating in the HDL cholesterol kits market are Diazyme Laboratories, Inc., Randox Laboratories Limited, Fujifilm Holding Corporation, Thermo Fisher Scientific, Abcam plc., Merck KGaA, Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), PerkinElmer, Inc., and Hoffmann-La Roche Ltd.

Players in the HDL cholesterol kits market are focusing on partnerships and acquisitions with regional and global players to increase their sales worldwide. For instance, through the acquisition of Wako Pure Chemical, Fujifilm Holding Corporation expand its presence in the life science and chemical sectors.

The manufacturers of HDL cholesterol kits are focusing on the expansion of their presence in key markets such as the Asia Pacific, the Middle East, and Europe through distribution agreements and the opening of new manufacturing facilities.

The manufacturers of HDL cholesterol kits are also focusing on the development of point-of-care testing as it is more helpful and convenient for making quicker decisions. Moreover, HDL cholesterol kits industry stakeholders are focusing on the addition of direct reagent kits in their product portfolios

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/9842

HDL Cholesterol Kits Market by Category

Product Type:

  • HDL Cholesterol Precipitating Reagent Kit
  • HDL Cholesterol Direct Reagent Kit
  • HDL and LDL/VLDL Assay Kit

End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

Region:

  • North America
  • Latin America
  • Europe
  • Oceania
  • East Asia
  • South Asia
  • Middle East & Africa (MEA)

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

 

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

 

Deflectable Catheters Market is projected to expand at a CAGR of 3.9% from 2022 to 2029

Deflectable catheters are used for minimally invasive procedures such as coronary interventions and electrophysiology applications. Due to the upgradation of technology, the core tip can deflect at a certain angle. According to the latest research by FMI, the global deflectable catheters market is expected to account for more than US$ 2,400.0 Mn in terms of value by the end of 2029. The deflectable catheters market report also projects a significant growth potential in the market with a CAGR of ~ 4% during the forecast period.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5852
Companies Eyeing Untapped Opportunities in Cost-sensitive Regional Markets

The current adoption pattern among healthcare professionals favour the use of reposable medical devices, a trend that is most certainly observed in developing countries, to complement the cost factor and availability. In contrast, most of the deflectable catheters used are one-time use products. Factors like blood, debris prevent using reposable deflectable catheters in operations as critical as electrophysiology.

The usage of reposable deflectable catheters is significantly higher in developing economies with inadequate resources, where the cost of treatment can be significantly high, which is unfavourable for patients from poor backgrounds. The present cost structure with the use of reposable deflectable catheters makes it feasible for a sizeable population to opt for low-cost treatment options, which help boost the adoption rate, and thereby expand the consumer pool.

At present, there are only a few companies offering reposable deflectable catheters, and none of the major players are into developing reposable devices. As per the report, a comparatively smaller company, CathRx, has a similar reposable product, Khelix, which is considered to be the first ‘reposable’ diagnostic and therapeutic catheter for the treatment of cardiac arrhythmias.

Acquisitions & Collaborations Playing Decisive Role in Shaping Deflectable Catheters Market Structure

The affective adjustments and development observed in the parent market influences the deflectable catheters market. The recent trend of involving digital methods for diagnosing cardiac problems is also changing the treatment pattern. All these trends are more governed by the top market leaders in the cardiology market. With abundant resources and investment plans, they manipulate the industry in a way in which no other smaller or regional manufacturer is capable of keeping pace with them.

The trend of acquisition and forming a strategic partnership is positive delivering financial results. For example, Abbott’s acquisition of St. Jude Medical resulted in the consolidation of the 2nd and 4th largest cardiology market players. Moreover, the acquisition of specific treatment technologies has also been observed in the deflectable catheter market, and there has been an increase in the number of players expanding their product portfolio for the treatment of atrial fibrillation/atrial flutter.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-5852

Deflectable Catheters Market: Segmental Analysis

On the basis of product type, the deflectable catheters market has been segmented into uni-directional deflectable catheters, bi-directional deflectable catheters, and multi-directional deflectable catheters. Bi-directional deflectable catheters lead the market due to their high adoption rate and availability.

Based on application, the deflectable catheters market has been segmented into coronary interventions, electrophysiology, diagnostics imaging, and peripheral interventions. In terms of revenue, the electrophysiology segment is expected to have a major share in the deflectable catheters market due to an increase in the number of procedures being carried out by deflectable catheters.

On the basis of end user, the deflectable catheters market has been categorised into hospitals, office-based clinics, ambulatory surgical centres, and independent catheterisation labs. Independent catheterisation labs are expected to witness significant growth, which is driven by an increase in the number of the same.

Some of the key players in the deflectable catheters market include Medtronic Plc, Merit Medical Systems, JOHNSON & JOHNSON, Teleflex Incorporated, Boston Scientific Corporation, Biomerics LLC, OSYPKA AG, Abbott, Japan Lifeline Co., CathRx Ltd., and Biotronik SE & Co. KG.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-5852

HDL Cholesterol Kits Market by Category

Product Type:

  • HDL Cholesterol Precipitating Reagent Kit
  • HDL Cholesterol Direct Reagent Kit
  • HDL and LDL/VLDL Assay Kit

End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

Region:

  • North America
  • Latin America
  • Europe
  • Oceania
  • East Asia
  • South Asia
  • Middle East & Africa (MEA)

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

 

Surgical Booms Market is projected to grow at a moderate CAGR of 4.7% between 2022 and 2029

Surgical booms are also known as Equipment Management Systems (EMS). Surgical booms are used to constrain electrical wiring from the various equipment used in the OR. They also help organise the space in the OR by increasing the working space. Most surgical booms are suspended from the roof of the OR and are available in a number of designs and utilities.

According to the latest research by FMI, the global surgical booms market is expected to account for more than US$ 380.2 Million in terms of value by the end of 2029. The surgical booms market report also projects significant growth potential with an anticipated average Y-o-Y growth rate of over 4.7% during the forecast period.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4375

Increase in the Adoption of Minimally Invasive Surgeries is Likely to Drive the Growth of the Surgical Booms Market

Minimally Invasive Surgery (MIS) is one of the major trends in medicine. MIS is a safe, feasible, and patient-friendly method of performing medical procedures such as surgery. MIS offers reduced postoperative pain, shorter length of stay in a hospital, lesser scarring or damage to tissues, and generally leads to faster recovery. Hence, MIS is easier and less time-consuming.

As clinicians seek safer and more efficient ways to perform surgery, they find new applications for minimally invasive procedures, because the benefits of the same for patients are paramount. Furthermore, the increasing number of insurance providers that offer reimbursement for costs incurred during most minimally invasive procedures is expected to increase the adoption rate of minimally invasive surgeries.

The Centers for Medicare and Medicaid Services (CMS) provides reimbursement for peripheral access procedures, such as the insertion of a port or catheter into a large central artery that is directly related to or is near the heart. Thus, increase in the number of minimally invasive surgeries is boosting the demand for equipment management systems such as equipment booms.

High Capital Investment for Integrated OR to Hinder the Growth of Surgical Booms Market

Integrated ORs utilise a crossover of medical interventions to form hybrid technologies. The development and integration of ORs requires the re-organization of professionals. In addition, there is a need to upgrade the capital equipment. Cost of such advanced capital equipment is high.

Furthermore, compatibility with existing or new devices/infrastructure is likely to present a hurdle for the designers, manufacturers, and end users of surgical booms. A hybrid OR, on an average, requires 50-80% more space as compared to a conventional OR in the U.S., and 30-40% more in Germany.

The additional space required is another factor that is likely to increase the cost of the setup of an integrated OR. Thus, the capital cost required for an integrated OR is likely to hinder the growth of the surgical booms market.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-4375

Surgical Booms Market: Segmental Analysis

The global surgical booms market has been segmented on the basis of product, installation, and end user. On the basis of product type, the surgical booms market has been segmented into equipment booms, utility booms, anaesthesia booms, and custom booms. Custom booms lead the market due to the flexibility of choice the customers have from manufacturers.

Based on installation, the surgical booms market has been segmented into roof mounting and floor mounting. In terms of revenue, the roof mounting segment is expected to have a major share in the surgical booms market during the forecast period as these are more flexible and conserve space in the OR more effectively.

On the basis of end user, the surgical booms market has been categorised into hospitals, ambulatory surgical centres, specialty clinics, and hybrid operating rooms. The revenue generated by the hospitals segment of the surgical booms market is expected to witness significant growth, which is driven by the presence of a large number of ORs and associated ICU departments at various hospitals.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/4375

Surgical Booms Market: Companies

Some of the key players in the surgical booms market include CV Medical LLC., Stryker Corporation, Hill Rom Holdings Inc., Amico Group of Companies, Steris Plc, Ondal Medical Systems GmbH, Getinge Group, Pratibha Medinox, Skytron LLc, and Palakkad Surgical Industries, among others.

Surgical Booms Market by Category

By Product:

  • Equipment Booms
  • Utility Booms
  • Anesthesia Booms
  • Custom Booms

By End User;

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Hybrid Operating Rooms

By Installation:

  • Roof Mounting
  • Floor Mounting

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

 

Gene Editing Tools Market Expanding at a healthy 18.8% CAGR, the market size is projected to total US$ 1.6 Bn by 2029

According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 481.3 Mn in terms of value in 2022. The report on the gene editing tools market further projects that the gene editing tools market is likely to grow at a CAGR of over 18.8% during the period 2022-2029.

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) segment is a leading segment in terms of revenue by product type in the gene editing tools market, and accounted for an approximate revenue share of 75% in 2018. CRISPR/Cas9 gene editing tools are most widely used by scientists to create transgenic animals that include zebrafish, pigs, mice, rats, and primates. Among all the distribution channels in the gene editing tools market, the academic and research institutes segment is expected to be most prominent segment, followed by biotech and pharmaceutical companies.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9544
Prevalence of Cancers and Rare Genetic Diseases Establish a Strong Base for Innovation of Gene Editing Tools

The rising prevalence of cancer and other genetic disorders, such as sickle cell disease, heart disease, diabetes, Alzheimer’s disease, obesity, and others, is among the key factors impacting the growth of gene editing tools market. Cancer is registered to be the second most prominent cause of death worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, cancer alone was responsible for an estimated 9.6 million deaths globally in 2021.

Worldwide, approximately about 1 in 6 deaths occur owing to cancer. An analysis states that approximately 70% of deaths due to cancer occur in low- and middle-income countries. Thus, gene editing is most preferred for the management of rare genetic disorders, which is driving the demand for gene editing, thus generating a favourable revenue opportunity for gene editing tools.

The growing prevalence and incidence of rare genetic disorders, majorly Sickle Cell Disease (SKD), cancer, and Alzheimer’s disease, is leading to the high demand for genome editing, and is one of the leading factors that is contributing significantly to the growth of the gene editing tools market. Moreover, gene editing tools, such as CRISPR, TALENs, and ZFNs, find precise applications in the treatment of cancer. Owing to the high efficiency and accuracy of the CRISPR-Cas9 gene editing technique, it has emerged as a potential tool for cancer therapy. Among its various applications, CRISPR-Cas9 has a high clinical potential to detect novel target genes for cancer therapy.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-9544

Biomedical Community Eyes Potential Application of Gene Editing Tools

Introduction of technologically advanced gene editing tools is expected to boost the growth of gene editing tools market. Recent advancements in CRISPR gene editing tools and their ease of use have generated significant interest in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing has high potential to cater to the therapeutic landscape of induced disorders, owing to the presence of key players in the industry such as Intellia, CRISPR Therapeutics, and Editas. CRISPR gene editing tools offer precise gene-targeted treatments for β-thalassemia and SKD. Among gene editing tools, there are potential applications for CRISPR in the gene editing tools market in human therapeutics as well as veterinary therapeutics.

Regional Players Focusing on Product Reach & Connectivity

North America, followed by Europe, is a prominent region in the global gene editing tools market. North America accounts for a revenue share of about 25.0% in 2021 in gene editing tools market. Europe accounting for the second-largest revenue share, and is followed by South Asia in the gene editing tools market. India, China, and Japan are among the emerging markets in the gene editing tools market. Japan is among the fastest-growing emerging markets in the global gene editing tools market, and is projected to grow at a CAGR of more than 6% during the forecast period of 2022-2028.

The gene editing tools market report tracks some of the key companies operating in gene editing tools market, such as Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS, Merck KGaA, Editas Medicine, Takara Bio USA, New England Biolabs, Intellia Therapeutics, Inc., and GenScript Biotech Corporation. Majority of the key regional players in the gene editing tools market are focused on increasing their product reach and connectivity with the help of domestic distributors of gene editing tools. Moreover, the manufacturers of gene editing tools are focused to strengthening their businesses in high-growth markets, such as India, Japan, China, and Argentina, by expanding their sales and distribution channels across these countries.

Ask Us Your Questions About This Report: https://www.futuremarketinsights.com/ask-question/rep-gb-9544

Gene Editing Tools Market by Category

BY Product:

  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9)
  • Zinc Finger Nucleases (ZFNs)
  • Transcription Activator-Like Effector Nucleases (TALENs)
  • Viral Systems
  • Transposon Systems
  • Others

BY Application:

  • Veterinary Medicine
  • Cell Line Engineering
  • Bioremediation
  • Food and Brewing Development
  • Food Waste Management
  • Bio sensing Development
  • Others

BY End User:

  • Biotech and Pharma Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Food Industry
  • Others

BY Region:

  • North America
  • Latin America
  • Europe
  • Oceania
  • East Asia
  • South Asia
  • Middle East & Africa (MEA)

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

 

Mucopolysaccharidosis (MPS) Treatment Market is projected to grow at a robust CAGR of 5.9% between 2022 and 2029

A market study presented by FMI ‘ Mucopolysaccharidosis Treatment Market is estimated to be worth around US$ 2.38 Bn in 2022 at a robust CAGR of 5.9% between 2022 and 2029

According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there is a significant shortage of medical and scientific data related to it. Mucopolysaccharidosis treatment and diagnosis involves complex managing requirements, which include long-term care, rehabilitation support, and a continuous treatment plan.

Get a Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Research Activities Uplift Stem Cell Therapy Application in MPS Treatment

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the mucopolysaccharidosis treatment market, it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-5880

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

The mucopolysaccharidosis treatment market includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present mucopolysaccharidosis treatment market. The currently existing promising drug types are expected to face competition from emerging candidates. In addition the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

Ask Us Your Questions About This Report: https://www.futuremarketinsights.com/ask-question/rep-gb-5880

Mucopolysaccharidosis Treatment Market by Category

Treatment

  • Enzyme Replacement Therapies
  • Stem Cell Therapies
    • Bone Marrow Transplantation
    • Umbilical Cord Blood Transplantation

Type of MPS

  • MPS I
  • MPS II
  • MPS IV A
  • MPS VI
  • MPS VII

End User

  • Hospital
  • Specialty Clinics
  • Medical Research Centers
  • Home-infusion

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

 

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

 

Disposable Spinal Instruments Market is poised to increase at a robust CAGR of 8.3% between 2022 and 2028

Healthcare-Associated Infections or Hospital-Acquired Infections (HAIs) are caused while receiving medical treatment in a hospital facility. HAIs are among the major challenges to the safety of patients, and can have severe public health implications. These infections are also capable of causing disability and sometimes death. The occurrence of HAIs is increasing at an alarming rate. According to WHO, the prevalence of these infections in developed countries varies from 3.5% to 12%. Developing countries are at a higher risk as the rate of infection is 3-20 times higher in developing countries as compared to high-income countries.

In the U.S., more than 15 Mn surgeries are performed annually. Between 2% and 5% of patients are estimated develop a surgical site infection, which is between 160,000 and 300,000 surgical site infections nationwide each year. Surgical site infections are among the most commonly occurring HAIs in the U.S., and are the most expensive to treat. Fortunately, the adoption of various disposable devices and kits has reduced the incidence of surgical site infections and HAIs.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-6890
Thus, the increasing preference for the usage of disposable instruments for reducing the occurrence of HAIs is driving the demand for disposable instruments, which is creating growth opportunities for the disposable spinal instruments market.

According to latest research by FMI, the global disposable spinal instruments market is  is estimated to be worth around US$ 59.7 Mn in 2022. Owing to the rise in hospital acquired infection cases, the overall demand for disposable spinal instruments is poised to increase at a robust CAGR of 8.3% between 2022 and 2028, totaling a valuation of US$ 96.5 Mn by 2028

The demand for disposable instruments kits in the healthcare industry is growing at a significant rate, and the demand from unconventional end-use industries is one of the major factors fuelling the market for disposable spinal instruments. Growth in the number of end users, apart from hospitals, such as orthopaedic clinics and Ambulatory Surgical Centres (ASCs), is expected to create high demand for disposable spinal instruments. Moreover, the adoption of disposable instrument kits by various end users has reduced the risk of infections and cross-contamination, which has resulted in a reduction in the number of HAIs.

Increase in the number of use cases of disposable spinal instruments in hospitals and ASCs is expected to boost the global demand for disposable instrument kits. According to CDC, the number of Medicare-certified ASCs has increased steadily from 239 in 1983 to 5,316 in 2010.

Moreover, increasing geriatric population, which is prone to various types of spinal injuries, is estimated to boost the need for surgeries. This is expected to contribute to the demand for disposable spinal instruments. The increasing requirement of instrument kits during surgeries among the greying population, coupled with improved life expectancy, has created significant growth opportunities for the manufactures of disposable spinal instruments market. However, factors such as stringent regulations and the generation of a significant amount of waste due to the usage of disposable kits is expected to lower the growth of disposable spinal instruments in the forecast period.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-6890

The disposable spinal instruments kits segment is a leading segment in terms of revenue by product type in the disposable spinal instruments market, with a 64.5% revenue share in 2021. These kits are most widely used in cervical and lumbar surgeries such as spinal fusion and decompression surgeries. Among the procedure type segments, the spinal fusion sub-segment accounts for the largest revenue share in the disposable spinal instruments market. Among all the end users in the disposable spinal instruments market, the hospitals sub-segment is expected to be a prominent segment, followed by the orthopaedic clinics sub-segment.

The disposable spinal instruments market has been analysed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA. North America, followed by Europe, is a prominent region in the global disposable spinal instruments market. North America accounted for a revenue share of 45.8% in 2021 in disposable spinal instruments market. Europe, accounting for the second-largest revenue share, is followed by East Asia in the disposable spinal instruments market. India, China, and Brazil are emerging markets in the disposable spinal instruments market. China is one of the fastest-growing emerging markets in the global disposable spinal instruments market, and is projected to grow at a CAGR of 11.2% over the forecast period of 2022-2029.

The disposable spinal instruments market report tracks some of the key companies operating in the disposable spinal instruments market, such as ECA Medical, Providence Medical Technology, Inc., Xenco Medical, Paradigm Spine, Intelligent Implant Systems, LLC, Safe Orthopaedics, SA , TeDan Surgical Innovations, LLC, and Joimax GmbH. Majority of the regional players in the disposable spinal instruments market are focused on increasing their product reach and connectivity with the regional distributors of disposable spinal instruments. The manufacturers of disposable spinal instruments are focusing on collaborating with established hospitals and ASCs to sell products as some of the medical practitioners are particular about the type and brand of products used for a surgical procedure.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-6890

Disposable Spinal Instruments Market by Category

By Product Type :

  • Instrument Kits
  • Cervical
  • Lumbar
  • Systems
By Procedure:
  • Spinal Fusion
  • Decompression Surgeries
By End User:
  • Hospitals
  • Orthopaedic Clinics
  • Ambulatory Surgical Centers
By Region:
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

 

For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com